Clinical trial

Darolutamide+ADT Post-RP w/o ePLND in hrPC: Briganti 2019

NCT07282197

StatusNOT_YET_RECRUITING

Study typeINTERVENTIONAL

Start date2026-01-01

PhasePHASE2

Study timeline

Study start (estimated)2026-01-01Date precision: month

Registry last updated2025-12-15

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Prostate Cancerunresolved

Interventions

Darolutamide (BAY 1841788)DRUG

Sponsors & collaborators

Peking University First Hospitallead sponsor

Mapped research locations

BeijingChina1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07282197 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.